144 related articles for article (PubMed ID: 36549114)
1. Novel pyridine-containing histone deacetylase inhibitors strongly arrest proliferation, induce apoptosis and modulate miRNAs in cancer cells.
Di Bello E; Sian V; Bontempi G; Zwergel C; Fioravanti R; Noce B; Castiello C; Tomassi S; Corinti D; Passeri D; Pellicciari R; Mercurio C; Varasi M; Altucci L; Tripodi M; Strippoli R; Nebbioso A; Valente S; Mai A
Eur J Med Chem; 2023 Feb; 247():115022. PubMed ID: 36549114
[TBL] [Abstract][Full Text] [Related]
2. Novel Pyridine-Based Hydroxamates and 2'-Aminoanilides as Histone Deacetylase Inhibitors: Biochemical Profile and Anticancer Activity.
Zwergel C; Di Bello E; Fioravanti R; Conte M; Nebbioso A; Mazzone R; Brosch G; Mercurio C; Varasi M; Altucci L; Valente S; Mai A
ChemMedChem; 2021 Mar; 16(6):989-999. PubMed ID: 33220015
[TBL] [Abstract][Full Text] [Related]
3. Novel cinnamyl hydroxyamides and 2-aminoanilides as histone deacetylase inhibitors: apoptotic induction and cytodifferentiation activity.
Valente S; Tardugno M; Conte M; Cirilli R; Perrone A; Ragno R; Simeoni S; Tramontano A; Massa S; Nebbioso A; Miceli M; Franci G; Brosch G; Altucci L; Mai A
ChemMedChem; 2011 Apr; 6(4):698-712. PubMed ID: 21374822
[TBL] [Abstract][Full Text] [Related]
4. Structure-activity relationship and mechanistic studies for a series of cinnamyl hydroxamate histone deacetylase inhibitors.
Tavares MT; de Almeida LC; Kronenberger T; Monteiro Ferreira G; Fujii de Divitiis T; Franco Zannini Junqueira Toledo M; Mariko Aymoto Hassimotto N; Agostinho Machado-Neto J; Veras Costa-Lotufo L; Parise-Filho R
Bioorg Med Chem; 2021 Apr; 35():116085. PubMed ID: 33668008
[TBL] [Abstract][Full Text] [Related]
5. Development of Coumarin-Based Hydroxamates as Histone Deacetylase Inhibitors with Antitumor Activities.
Zhao N; Yang F; Han L; Qu Y; Ge D; Zhang H
Molecules; 2020 Feb; 25(3):. PubMed ID: 32046013
[TBL] [Abstract][Full Text] [Related]
6. R306465 is a novel potent inhibitor of class I histone deacetylases with broad-spectrum antitumoral activity against solid and haematological malignancies.
Arts J; Angibaud P; Mariën A; Floren W; Janssens B; King P; van Dun J; Janssen L; Geerts T; Tuman RW; Johnson DL; Andries L; Jung M; Janicot M; van Emelen K
Br J Cancer; 2007 Nov; 97(10):1344-53. PubMed ID: 18000499
[TBL] [Abstract][Full Text] [Related]
7. A novel histone deacetylase (HDAC) inhibitor MHY219 induces apoptosis via up-regulation of androgen receptor expression in human prostate cancer cells.
Patra N; De U; Kim TH; Lee YJ; Ahn MY; Kim ND; Yoon JH; Choi WS; Moon HR; Lee BM; Kim HS
Biomed Pharmacother; 2013 Jun; 67(5):407-15. PubMed ID: 23583193
[TBL] [Abstract][Full Text] [Related]
8. Design, synthesis, and biological evaluation of indole-based hydroxamic acid derivatives as histone deacetylase inhibitors.
Jiang BE; Hu J; Liu H; Liu Z; Wen Y; Liu M; Zhang HK; Pang X; Yu LF
Eur J Med Chem; 2022 Jan; 227():113893. PubMed ID: 34656899
[TBL] [Abstract][Full Text] [Related]
9. tert-Butylcarbamate-containing histone deacetylase inhibitors: apoptosis induction, cytodifferentiation, and antiproliferative activities in cancer cells.
Valente S; Trisciuoglio D; Tardugno M; Benedetti R; Labella D; Secci D; Mercurio C; Boggio R; Tomassi S; Di Maro S; Novellino E; Altucci L; Del Bufalo D; Mai A; Cosconati S
ChemMedChem; 2013 May; 8(5):800-11. PubMed ID: 23526814
[TBL] [Abstract][Full Text] [Related]
10. Utilization of cyanopyridine in design and synthesis of first-in-class anticancer dual acting PIM-1 kinase/HDAC inhibitors.
Bass AKA; Nageeb EM; El-Zoghbi MS; Mohamed MFA; Badr M; Abuo-Rahma GEA
Bioorg Chem; 2022 Feb; 119():105564. PubMed ID: 34959179
[TBL] [Abstract][Full Text] [Related]
11. Design, synthesis and biological evaluation of novel hydroxamates and 2-aminobenzamides as potent histone deacetylase inhibitors and antitumor agents.
Xie R; Yao Y; Tang P; Chen G; Liu X; Yun F; Cheng C; Wu X; Yuan Q
Eur J Med Chem; 2017 Jul; 134():1-12. PubMed ID: 28391133
[TBL] [Abstract][Full Text] [Related]
12. Design, Synthesis and Biological Evaluation of Novel Coumarin-Based Hydroxamate Derivatives as Histone Deacetylase (Hdac) Inhibitors with Antitumor Activities.
Yang F; Zhao N; Song J; Zhu K; Jiang CS; Shan P; Zhang H
Molecules; 2019 Jul; 24(14):. PubMed ID: 31311163
[TBL] [Abstract][Full Text] [Related]
13. Design, Synthesis and Biological Evaluation of Histone Deacetylase Inhibitors Based on Pyrrolo[2,3-d]pyrimidine and Pyrrolo[2,3-b]pyridine Scaffolds.
Mao ND; Gao Y; Dang XW; Duan JL; Hui Z; Che H; Xu Y; Zhang H; He X; Garrido C; Ye XY
ChemMedChem; 2023 Jul; 18(14):e202200683. PubMed ID: 37126396
[TBL] [Abstract][Full Text] [Related]
14. Synthesis, biological evaluation, and molecular docking analysis of novel linker-less benzamide based potent and selective HDAC3 inhibitors.
Routholla G; Pulya S; Patel T; Abdul Amin S; Adhikari N; Biswas S; Jha T; Ghosh B
Bioorg Chem; 2021 Sep; 114():105050. PubMed ID: 34120025
[TBL] [Abstract][Full Text] [Related]
15. Hydroxamic Acid Derivatives of β-Carboline/Hydroxycinnamic Acid Hybrids Inducing Apoptosis and Autophagy through the PI3K/Akt/mTOR Pathways.
Ling Y; Li Y; Zhu R; Qian J; Liu J; Gao W; Meng C; Miao J; Xiong B; Qiu X; Ling C; Dai H; Zhang Y
J Nat Prod; 2019 Jun; 82(6):1442-1450. PubMed ID: 31120744
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and anticancer activity of novel histone deacetylase inhibitors that inhibit autophagy and induce apoptosis.
Mo H; Zhang R; Chen Y; Li S; Wang Y; Zou W; Lin Q; Zhao DG; Du Y; Zhang K; Ma YY
Eur J Med Chem; 2022 Dec; 243():114705. PubMed ID: 36215854
[TBL] [Abstract][Full Text] [Related]
17. Discovery of aliphatic-chain hydroxamates containing indole derivatives with potent class I histone deacetylase inhibitory activities.
Chao SW; Chen LC; Yu CC; Liu CY; Lin TE; Guh JH; Wang CY; Chen CY; Hsu KC; Huang WJ
Eur J Med Chem; 2018 Jan; 143():792-805. PubMed ID: 29223096
[TBL] [Abstract][Full Text] [Related]
18. Anticancer effects of the MHY218 novel hydroxamic acid-derived histone deacetylase inhibitor in human ovarian cancer cells.
Jeon HS; Ahn MY; Park JH; Kim TH; Chun P; Kim WH; Kim J; Moon HR; Jung JH; Kim HS
Int J Oncol; 2010 Aug; 37(2):419-28. PubMed ID: 20596669
[TBL] [Abstract][Full Text] [Related]
19. The histone deacetylase inhibitor panobinostat exerts anticancer effects on esophageal squamous cell carcinoma cells by inducing cell cycle arrest.
Cheng YW; Liao LD; Yang Q; Chen Y; Nie PJ; Zhang XJ; Xie JJ; Shan BE; Zhao LM; Xu LY; Li EM
Cell Biochem Funct; 2018 Dec; 36(8):398-407. PubMed ID: 30484863
[TBL] [Abstract][Full Text] [Related]
20. Antitumor effects of a novel sulfur-containing hydroxamate histone deacetylase inhibitor H40.
Long J; Zhao J; Yan Z; Liu Z; Wang N
Int J Cancer; 2009 Mar; 124(5):1235-44. PubMed ID: 19058176
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
